NASDAQ:DNLI Denali Therapeutics (DNLI) Stock Price, News & Analysis → The Crypto 9-5 Escape Plan (From Crypto 101 Media) (Ad) Free DNLI Stock Alerts $18.31 -0.36 (-1.93%) (As of 05/10/2024 08:54 PM ET) Add Compare Share Share Today's Range$18.27▼$18.9550-Day Range$14.96▼$21.6952-Week Range$14.56▼$33.31Volume763,100 shsAverage Volume1.17 million shsMarket Capitalization$2.61 billionP/E RatioN/ADividend YieldN/APrice Target$40.22 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainabilityStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainability Get Denali Therapeutics alerts: Email Address Denali Therapeutics MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.89 Rating ScoreUpside/Downside119.7% Upside$40.22 Price TargetShort InterestBearish8.16% of Float Sold ShortDividend StrengthN/ASustainability-0.84Upright™ Environmental ScoreNews Sentiment0.30Based on 41 Articles This WeekInsider TradingSelling Shares$2.22 M Sold Last QuarterProj. Earnings GrowthGrowingFrom ($2.70) to ($2.66) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.4.40 out of 5 starsMedical Sector108th out of 925 stocksBiological Products, Except Diagnostic Industry12th out of 154 stocks 4.4 Analyst's Opinion Consensus RatingDenali Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.89, and is based on 8 buy ratings, 1 hold rating, and no sell ratings.Amount of Analyst CoverageDenali Therapeutics has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Denali Therapeutics' stock forecast and price target. Previous Next 1.0 Short Interest Percentage of Shares Shorted8.16% of the float of Denali Therapeutics has been sold short.Short Interest Ratio / Days to CoverDenali Therapeutics has a short interest ratio ("days to cover") of 8.3.Change versus previous monthShort interest in Denali Therapeutics has recently increased by 9.60%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldDenali Therapeutics does not currently pay a dividend.Dividend GrowthDenali Therapeutics does not have a long track record of dividend growth. Previous Next 4.7 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreDenali Therapeutics has received a 74.49% net impact score from Upright. The largest positive contribution comes from its "Creating knowledge" impact, which is mostly driven by its "Clinical research services for physiological diseases ", "Basic medical research services", and "Preclinical research services for physical health" products. See details.Environmental SustainabilityThe Environmental Impact score for Denali Therapeutics is -0.84. Previous Next 1.8 News and Social Media Coverage News SentimentDenali Therapeutics has a news sentiment score of 0.30. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.58 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 41 news articles for Denali Therapeutics this week, compared to 3 articles on an average week.Search InterestOnly 2 people have searched for DNLI on MarketBeat in the last 30 days. This is a decrease of -75% compared to the previous 30 days.MarketBeat FollowsOnly 6 people have added Denali Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of -40% compared to the previous 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Denali Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $2,218,802.00 in company stock.Percentage Held by InsidersOnly 7.90% of the stock of Denali Therapeutics is held by insiders.Percentage Held by Institutions92.92% of the stock of Denali Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Denali Therapeutics' insider trading history. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Denali Therapeutics are expected to grow in the coming year, from ($2.70) to ($2.66) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Denali Therapeutics is -19.07, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Denali Therapeutics is -19.07, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioDenali Therapeutics has a P/B Ratio of 1.79. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Denali Therapeutics' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Crypto 101 MediaThe Crypto 9-5 Escape PlanA brand-new guide from the host of one of the world's largest cryptocurrency podcasts lays out an action plan that could help you retire quickly and comfortably in today's crypto market.Click here to get instant access to the guide About Denali Therapeutics Stock (NASDAQ:DNLI)Denali Therapeutics Inc., a biopharmaceutical company, develops a portfolio of product candidates engineered to cross the blood-brain barrier for neurodegenerative diseases and lysosomal storage diseases in the United States. The company's transport vehicle (TV)-enabled programs include DNL310 ETV, an IDS enzyme replacement therapy program for MPS II; TAK-594/DNL593 which is in Phase 1/II for frontotemporal dementia-granulin; DNL126 program for MPS IIIA; and DNL622 for MPS I, as well as other preclinical programs that target amyloid beta and HER2. Its brain-penetrant small molecule programs comprise BIIB122/DNL151 LRRK2 inhibitor program for Parkinson's disease; SAR443820/DNL788 RIPK1 inhibitor program for CNS disease; DNL343 eIF2B Activator program for amyotrophic lateral sclerosis; and SAR443122/DNL758 RIPK1 inhibitor program for peripheral inflammatory diseases. It also provides early stage program include TAK-594/DNL593 program for FTD-GRN; DNL126 program for MPS IIIA, a Sanfilippo Syndrome A; DNL622 for MPS I which is Hurler syndrome; Antibody Transport Vehicle Amyloid beta program; Oligonucleotide Transport Vehicle platform, a novel class of biotherapeutics to address the root cause of diseases through modulation of gene expression; and other TV-enabled discovery programs. The company has collaboration agreements with Biogen MA Inc. and Biogen International GmbH; Genzyme Corporation; Takeda Pharmaceutical Company Limited; F-star Gamma Limited, F-star Biotechnologische Forschungs-und Entwicklungsges m.b.H, and F-star Biotechnology Limited; and Genentech, Inc. The company was formerly known as SPR Pharma Inc. and changed its name to Denali Therapeutics Inc. in March 2015. Denali Therapeutics Inc. was incorporated in 2013 and is headquartered in South San Francisco, California.Read More DNLI Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart DNLI Stock News HeadlinesApril 19, 2024 | insidertrades.comVicki L. Sato Sells 1,666 Shares of Denali Therapeutics Inc. (NASDAQ:DNLI) StockMay 13, 2024 | markets.businessinsider.comStifel Nicolaus Sticks to Their Hold Rating for Denali Therapeutics (DNLI)May 13, 2024 | The Tomorrow Investor (Ad)The Department of Defense Has a New Drone ContractorThe Department of Defense just granted a major advantage to a small UAV provider. Since 1998, this Nasdaq-listed company has been supplying drones for civilian, enterprise, and military purposes.May 13, 2024 | americanbankingnews.comFY2024 Earnings Forecast for Denali Therapeutics Inc. Issued By Cantor Fitzgerald (NASDAQ:DNLI)May 13, 2024 | americanbankingnews.comDenali Therapeutics Inc. (NASDAQ:DNLI) Expected to Earn Q2 2024 Earnings of ($0.62) Per ShareMay 13, 2024 | americanbankingnews.comB. Riley Comments on Denali Therapeutics Inc.'s Q2 2024 Earnings (NASDAQ:DNLI)May 13, 2024 | americanbankingnews.comQ2 2024 EPS Estimates for Denali Therapeutics Inc. (NASDAQ:DNLI) Increased by AnalystMay 12, 2024 | americanbankingnews.comDenali Therapeutics (NASDAQ:DNLI) Price Target Cut to $22.00 by Analysts at Stifel NicolausMay 13, 2024 | The Tomorrow Investor (Ad)The Department of Defense Has a New Drone ContractorThe Department of Defense just granted a major advantage to a small UAV provider. Since 1998, this Nasdaq-listed company has been supplying drones for civilian, enterprise, and military purposes.May 12, 2024 | americanbankingnews.comHC Wainwright Reaffirms Buy Rating for Denali Therapeutics (NASDAQ:DNLI)May 12, 2024 | americanbankingnews.comDenali Therapeutics Inc. (NASDAQ:DNLI) to Post FY2028 Earnings of $1.74 Per Share, Wedbush ForecastsMay 11, 2024 | americanbankingnews.comHC Wainwright Comments on Denali Therapeutics Inc.'s Q2 2024 Earnings (NASDAQ:DNLI)May 10, 2024 | markets.businessinsider.comPositive Outlook for Denali Therapeutics: Accelerated Approval and Financial Strategy Strengthening Market PositionMay 10, 2024 | markets.businessinsider.comOptimistic Outlook for Denali Therapeutics: Buy Rating Affirmed Amidst Positive ERT Developments and Strong Pipeline ProgressMay 10, 2024 | americanbankingnews.comAnalysts Issue Forecasts for Denali Therapeutics Inc.'s FY2027 Earnings (NASDAQ:DNLI)May 9, 2024 | finance.yahoo.comDenali Therapeutics First Quarter 2024 Earnings: US$0.68 loss per share (vs US$0.80 loss in 1Q 2023)May 9, 2024 | americanbankingnews.comDenali Therapeutics (NASDAQ:DNLI) Trading Up 11.6% on Strong EarningsMay 7, 2024 | finance.yahoo.comDenali Therapeutics Q1 2024 Earnings: Misses Revenue Estimates Amid Strategic ShiftsMay 7, 2024 | finance.yahoo.comDenali Therapeutics Reports First Quarter 2024 Financial Results and Business HighlightsMay 7, 2024 | globenewswire.comDenali Therapeutics Reports First Quarter 2024 Financial Results and Business HighlightsMay 5, 2024 | americanbankingnews.comDenali Therapeutics Inc. (NASDAQ:DNLI) Receives Consensus Recommendation of "Buy" from AnalystsMay 2, 2024 | markets.businessinsider.comBuy Recommendation for DNLI: Promising Safety and Efficacy of Denali’s ALS Drug DNL343May 1, 2024 | globenewswire.comDenali Therapeutics Announces Completion of Enrollment for Regimen G Evaluating eIF2B Agonist DNL343 in the Phase 2/3 HEALEY ALS Platform TrialApril 29, 2024 | finance.yahoo.comIs There An Opportunity With Denali Therapeutics Inc.'s (NASDAQ:DNLI) 50% Undervaluation?April 20, 2024 | nasdaq.comOversold Conditions For Denali Therapeutics (DNLI)April 17, 2024 | msn.comDenali Therapeutics (DNLI) Price Target Decreased by 5.45% to 42.01April 8, 2024 | tmcnet.comFlagship Appoints Amy O'Shea as CEO-Partner and Chief Executive Officer of Invaio SciencesSee More Headlines Receive DNLI Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Denali Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/07/2024Today5/13/2024Next Earnings (Estimated)8/13/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological products, except diagnostic Sub-IndustryN/A Current SymbolNASDAQ:DNLI CUSIPN/A CIK1714899 Webwww.denalitherapeutics.com Phone(615) 866-8548FaxN/AEmployees445Year Founded2015Price Target and Rating Average Stock Price Target$40.22 High Stock Price Target$95.00 Low Stock Price Target$22.00 Potential Upside/Downside+119.7%Consensus RatingModerate Buy Rating Score (0-4)2.89 Research Coverage9 Analysts Profitability EPS (Most Recent Fiscal Year)($0.96) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-145,220,000.00 Net Margins-36.51% Pretax Margin-46.45% Return on Equity-11.46% Return on Assets-10.40% Debt Debt-to-Equity RatioN/A Current Ratio11.79 Quick Ratio13.65 Sales & Book Value Annual Sales$330.53 million Price / Sales7.90 Cash FlowN/A Price / Cash FlowN/A Book Value$10.21 per share Price / Book1.79Miscellaneous Outstanding Shares142,610,000Free Float131,343,000Market Cap$2.61 billion OptionableOptionable Beta1.39 Social Links Metaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free Report Key ExecutivesDr. Ryan J. Watts Ph.D. (Age 48)Co-Founder, President, CEO & Director Comp: $1.15MDr. Alexander O. Schuth M.D. (Age 51)Co-Founder, CFO, COO & Secretary Comp: $802.29kDr. Marc Tessier-Lavigne Ph.D. (Age 64)Co-Founder & Independent Director Comp: $57.5kDr. Carole Ho M.D. (Age 51)Chief Medical Officer & Head of Development Comp: $802.29kMr. Tyler M. Nielsen (Age 46)Senior Vice President of Corporate Finance Dr. Dana AndersenChief Technical and Manufacturing OfficerMr. Joe Lewcock Ph.D.Chief Scientific OfficerDr. Laura HansenVice President of Investor RelationsMr. Chris WalshGeneral CounselMr. Mark RowenVice President of Corporate DevelopmentMore ExecutivesKey CompetitorsVericelNASDAQ:VCELKymera TherapeuticsNASDAQ:KYMRTwist BioscienceNASDAQ:TWSTCG OncologyNASDAQ:CGONApogee TherapeuticsNASDAQ:APGEView All CompetitorsInsiders & InstitutionsEdgestream Partners L.P.Bought 112,118 shares on 5/11/2024Ownership: 0.079%Covestor LtdBought 3,589 shares on 5/11/2024Ownership: 0.008%Vanguard Group Inc.Bought 133,810 shares on 5/10/2024Ownership: 7.695%State Board of Administration of Florida Retirement SystemSold 1,430 shares on 5/9/2024Ownership: 0.023%ProShare Advisors LLCBought 2,820 shares on 5/8/2024Ownership: 0.022%View All Insider TransactionsView All Institutional Transactions DNLI Stock Analysis - Frequently Asked Questions Should I buy or sell Denali Therapeutics stock right now? 9 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Denali Therapeutics in the last year. There are currently 1 hold rating and 8 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" DNLI shares. View DNLI analyst ratings or view top-rated stocks. What is Denali Therapeutics' stock price target for 2024? 9 Wall Street research analysts have issued 12-month price targets for Denali Therapeutics' shares. Their DNLI share price targets range from $22.00 to $95.00. On average, they predict the company's share price to reach $40.22 in the next year. This suggests a possible upside of 119.7% from the stock's current price. View analysts price targets for DNLI or view top-rated stocks among Wall Street analysts. How have DNLI shares performed in 2024? Denali Therapeutics' stock was trading at $21.46 at the start of the year. Since then, DNLI shares have decreased by 14.7% and is now trading at $18.31. View the best growth stocks for 2024 here. When is Denali Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Tuesday, August 13th 2024. View our DNLI earnings forecast. How were Denali Therapeutics' earnings last quarter? Denali Therapeutics Inc. (NASDAQ:DNLI) announced its earnings results on Tuesday, May, 7th. The company reported ($0.68) EPS for the quarter, topping the consensus estimate of ($0.69) by $0.01. Denali Therapeutics had a negative trailing twelve-month return on equity of 11.46% and a negative net margin of 36.51%. During the same quarter in the previous year, the firm earned ($0.80) EPS. What ETFs hold Denali Therapeutics' stock? ETFs with the largest weight of Denali Therapeutics (NASDAQ:DNLI) stock in their portfolio include ALPS Medical Breakthroughs ETF (SBIO).BNY Mellon Innovators ETF (BKIV). What is Ryan Watts' approval rating as Denali Therapeutics' CEO? 1 employees have rated Denali Therapeutics Chief Executive Officer Ryan Watts on Glassdoor.com. Ryan Watts has an approval rating of 100% among the company's employees. This puts Ryan Watts in the top 10% of approval ratings compared to other CEOs of publicly-traded companies. What other stocks do shareholders of Denali Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Denali Therapeutics investors own include Progenics Pharmaceuticals (PGNX), Editas Medicine (EDIT), Intellia Therapeutics (NTLA), Sangamo Therapeutics (SGMO), Kratos Defense & Security Solutions (KTOS), CRISPR Therapeutics (CRSP), Anavex Life Sciences (AVXL), NVIDIA (NVDA), Invitae (NVTA) and Pretium Resources (PVG). When did Denali Therapeutics IPO? Denali Therapeutics (DNLI) raised $149 million in an initial public offering on Friday, December 8th 2017. The company issued 8,300,000 shares at $17.00-$19.00 per share. Goldman Sachs, Morgan Stanley and J.P. Morgan served as the underwriters for the IPO and Evercore ISI was co-manager. Who are Denali Therapeutics' major shareholders? Denali Therapeutics' stock is owned by many different institutional and retail investors. Top institutional investors include Baillie Gifford & Co. (9.85%), Vanguard Group Inc. (7.69%), Principal Financial Group Inc. (0.79%), Wasatch Advisors LP (0.29%), Swiss National Bank (0.15%) and Susquehanna Fundamental Investments LLC (0.15%). Insiders that own company stock include Alexander O Schuth, Alexander O Schuth, Carole Ho, Marc Tessier-Lavigne, Ryan J Watts, Ryan J Watts, Steve E Krognes, Steve E Krognes, Vicki L Sato and Vicki L Sato. View institutional ownership trends. How do I buy shares of Denali Therapeutics? Shares of DNLI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:DNLI) was last updated on 5/13/2024 by MarketBeat.com Staff From Our PartnersBill Clinton Backing Biden Replacement???The Freeport SocietyThe Department of Defense Has a New Drone ContractorThe Tomorrow InvestorHe Is Giving Away BitcoinCrypto Swap ProfitsThe A.I. story nobody is telling you (Read ASAP)TradeSmithThe Crypto 9-5 Escape PlanCrypto 101 MediaProtect Your Bank Account Before It’s Too LateWeiss RatingsCharles Payne Demystifies OptionsUnstoppable ProsperityElon’s New Device is About to Shock the WorldInvestorPlace Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Denali Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.